Immuneering (IMRX) Income towards Parent Company (2020 - 2023)
Historic Income towards Parent Company for Immuneering (IMRX) over the last 4 years, with Q4 2023 value amounting to -$15.5 million.
- Immuneering's Income towards Parent Company fell 1543.57% to -$15.5 million in Q4 2023 from the same period last year, while for Sep 2024 it was -$15.5 million, marking a year-over-year increase of 7051.25%. This contributed to the annual value of -$54.8 million for FY2023, which is 849.74% down from last year.
- As of Q4 2023, Immuneering's Income towards Parent Company stood at -$15.5 million, which was down 1543.57% from -$13.1 million recorded in Q3 2023.
- Immuneering's 5-year Income towards Parent Company high stood at -$3.6 million for Q2 2020, and its period low was -$15.5 million during Q4 2023.
- Over the past 4 years, Immuneering's median Income towards Parent Company value was -$11.5 million (recorded in 2022), while the average stood at -$10.2 million.
- In the last 5 years, Immuneering's Income towards Parent Company tumbled by 12162.34% in 2021 and then tumbled by 81.48% in 2023.
- Quarter analysis of 4 years shows Immuneering's Income towards Parent Company stood at -$5.8 million in 2020, then crashed by 88.02% to -$11.0 million in 2021, then decreased by 22.75% to -$13.5 million in 2022, then dropped by 15.44% to -$15.5 million in 2023.
- Its last three reported values are -$15.5 million in Q4 2023, -$13.1 million for Q3 2023, and -$12.3 million during Q2 2023.